Finding Cancer, Creating Solutions, Saving Lives.

Cangen is a new venture biotechnology company that discovers, develops, and commercializes diagnostics for significant unmet medical needs in oncology. Cangen anticipates commercializing its first product a GMP based bladder cancer kit in 2010. This product is licensed and based on Johns Hopkins University technology. Additional pipeline products include lung cancer detection.  Cangen was organized as a Texas Corporation and was incorporated in 2000.

 

Cangen’s principal strategy is to develop a complementary suite of cancer diagnostics and therapeutic enhancements in order to enable the large scale detection and effective treatment of a wide variety of cancers at early stages, including the ability to detect the presence of particular forms of cancer at the molecular level.  Cangen intends to do this by focusing resources and efforts on short and long term key objectives, by leveraging significant assets, and by maintaining and continuing to develop strategic alliances with key industry leaders throughout the world.

 

Cangen maintains ongoing collaborations with such industry leaders as Johns Hopkins, Olympus, Fuji Film and Dai Nippon Printing.  We hold many pivotal patents on our technology and products.

Copyright © 2010 Cangen Biotechnologies, Inc. All Rights Reserved.